Key Financials Snapshot

TTM · Consolidated · ₹ in Cr
Market Cap
₹1442 Cr.
Stock P/E
41.6
P/B
1.4
Current Price
₹133.6
Book Value
₹ 94
Face Value
10
52W High
₹271.5
52W Low
₹ 125.7
Dividend Yield
0%

Shalby Overview

Business

Shalby Ltd. is a leading multi-specialty hospital chain based in India. The company operates a network of hospitals primarily offering tertiary and quaternary healthcare services. Its core business model revolves around providing comprehensive medical care, including advanced surgical procedures, medical consultations, diagnostics, and emergency services. Shalby is particularly renowned for its orthopedic services, especially joint replacement surgeries (knee, hip, shoulder), and it has a strong focus on high-end tertiary care. The company makes money through patient charges for medical services, procedures, room occupancy, diagnostics, pharmacy sales, and international patient services.

Revenue Mix

Shalby Ltd. primarily operates within a single business segment: Hospital & Healthcare Services. While specific percentage breakdowns of revenue by medical specialty are not publicly disaggregated consistently, a significant portion of its revenue is historically derived from orthopedics, particularly joint replacement surgeries. Other key specialties contributing to revenue include cardiology, neurology, oncology, renal sciences, and critical care. Revenue is generated from a mix of domestic and international patients, with a strong emphasis on inpatient surgical procedures.

Industry

The Indian hospital industry is fragmented but witnessing consolidation, with both large corporate chains and standalone hospitals. It is characterized by increasing demand driven by population growth, rising disposable incomes, lifestyle diseases, and improving insurance penetration. Shalby Ltd. is positioned as a mid-sized to large multi-specialty hospital chain with a strong brand recall in orthopedics, particularly joint replacements. It competes with larger chains like Apollo Hospitals, Fortis Healthcare, Max Healthcare, and smaller regional players. Shalby has a significant presence in Western and Central India (Gujarat, Rajasthan, MP) and aims for a pan-India footprint. Its focus on specialized, high-acuity care differentiates it from general practitioners and primary care centers.

MOAT

Shalby's primary competitive advantage stems from its specialized expertise and reputation in orthopedics, particularly joint replacement surgeries, often associated with its founder, Dr. Vikram Shah. This specialization has built a strong brand equity and patient trust in this niche. The company also benefits from:

Scale in Specialty: High volume of joint replacement surgeries contributes to surgeon expertise and operational efficiency.

Doctor-led Model: Strong relationships with experienced doctors, particularly in its core specialties.

Regional Dominance: Established presence and brand in key regions like Gujarat.

However, the overall healthcare industry faces high competition, and while Shalby has a niche, it generally operates in a highly competitive market where switching costs for general healthcare services can be moderate.

Growth Drivers

Increasing Healthcare Expenditure: Rising income levels, greater health awareness, and increased health insurance penetration are boosting demand for quality healthcare.

Medical Tourism: India's cost-effectiveness and quality of care attract international patients, especially for complex surgeries like joint replacements.

Expansion & Bed Capacity Addition: The company's strategy includes organic expansion (adding beds in existing hospitals) and inorganic growth (acquisitions, tie-ups, management contracts) to expand its geographical reach.

Focus on High-Demand Specialties: Continued emphasis on orthopedic, cardiac, oncology, and other tertiary care services which have high growth potential.

Aging Population & Lifestyle Diseases: An aging population and increasing prevalence of chronic and lifestyle-related diseases drive demand for specialized medical interventions.

Risks

Intense Competition: Highly competitive landscape from existing large hospital chains, regional players, and new entrants.

Regulatory Risks: Government interventions like price caps on medical procedures (e.g., knee implants), drug pricing controls, and evolving healthcare policies can impact profitability.

Doctor & Staff Retention: Reliance on skilled medical professionals makes recruitment and retention a critical challenge and cost factor.

Capital Intensive Business: Hospital expansion and technology upgrades require significant capital expenditure, potentially impacting financial leverage.

Operational Challenges: Managing a large network of hospitals effectively, maintaining quality standards, and controlling operating costs are ongoing challenges.

Pandemic-Related Disruptions: Future health crises could lead to deferral of elective surgeries and impact patient footfalls.

Management & Ownership

Shalby Ltd. was founded by Dr. Vikram Shah, a renowned joint replacement surgeon, who serves as the Chairman and Managing Director. The company is promoter-led, with Dr. Shah and his family holding a significant stake, reflecting a strong vested interest in the company's performance. The management team comprises experienced professionals from the healthcare and finance sectors. The promoter group's substantial ownership demonstrates commitment and long-term vision. Institutional and public shareholders form the remainder of the ownership structure.

Outlook

Shalby Ltd. is well-positioned to benefit from the growing Indian healthcare market, particularly with its established brand in orthopedics and expansion plans. The increasing demand for quality healthcare, driven by demographics and rising affluence, provides a strong tailwind. The company's strategy of expanding its hospital network through a mix of owned, leased, and managed assets, coupled with a focus on high-acuity specialties, offers potential for sustained revenue and profitability growth. However, the outlook is tempered by intense competition, the capital-intensive nature of the hospital business, and potential regulatory pressures on pricing. Efficient execution of expansion plans, effective cost management, and diversification beyond its core orthopedic strength will be crucial for long-term success, while balancing the risks posed by a competitive and evolving regulatory environment.

Shalby Share Price

Live · BSE / NSE · Inception: 2004
₹ | |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Consolidated · annual

Shalby Quarterly Results

#(Fig in Cr.) Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 244 279 268 276 265 296 285 272 287 331
Other Income 5 10 7 5 5 7 4 7 8 7
Total Income 249 289 275 281 270 303 290 279 296 339
Total Expenditure 205 234 235 242 244 255 244 242 258 290
Operating Profit 44 55 40 39 26 49 46 37 37 49
Interest 6 8 9 11 11 9 10 11 9 11
Depreciation 16 16 17 16 16 17 17 18 18 19
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 22 30 14 12 -1 23 19 9 10 20
Provision for Tax 6 16 11 15 11 15 12 8 -9 9
Profit After Tax 16 15 2 -3 -12 8 7 1 18 10
Adjustments 1 1 1 1 1 1 1 0 -0 0
Profit After Adjustments 17 16 3 -2 -11 9 8 2 18 11
Adjusted Earnings Per Share 1.5 1.5 0.3 -0.2 -1 0.8 0.8 0.2 1.7 1

Shalby Profit & Loss

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Net Sales 290 324 378 462 487 431 699 805 934 1087 1141 1175
Other Income 2 7 10 9 17 9 12 23 19 28 27 26
Total Income 293 331 388 472 504 440 711 827 953 1115 1168 1204
Total Expenditure 235 252 299 379 404 344 577 667 755 952 996 1034
Operating Profit 58 78 89 93 100 96 134 161 198 162 172 169
Interest 10 11 12 9 7 5 8 11 18 41 41 41
Depreciation 11 17 23 33 36 37 43 48 52 66 70 72
Exceptional Income / Expenses 0 0 0 0 0 0 -4 0 0 0 0 0
Profit Before Tax 36 50 54 50 57 55 79 102 128 56 61 58
Provision for Tax -0 22 15 19 29 13 25 34 45 54 26 20
Profit After Tax 36 29 39 32 28 42 54 68 83 2 35 36
Adjustments 1 1 0 0 0 0 0 0 1 4 3 1
Profit After Adjustments 38 30 39 32 28 42 54 68 84 6 37 39
Adjusted Earnings Per Share 0 0 3.6 2.9 2.6 3.9 5 6.3 7.8 0.6 3.5 3.7

Shalby Balance Sheet

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Shareholder's Funds 205 251 751 780 799 835 876 928 1000 992 1005
Minority's Interest 0 -1 0 0 0 0 -0 -0 7 3 0
Borrowings 201 285 75 57 49 36 87 67 176 137 153
Other Non-Current Liabilities 6 5 65 73 96 115 146 202 212 153 168
Total Current Liabilities 92 199 138 88 83 82 172 194 323 455 576
Total Liabilities 504 741 1030 998 1027 1066 1282 1391 1719 1740 1902
Fixed Assets 319 323 650 692 672 660 675 685 966 955 1046
Other Non-Current Assets 120 259 144 109 121 136 158 189 200 127 137
Total Current Assets 64 159 236 197 234 271 442 517 552 658 719
Total Assets 504 741 1030 998 1027 1066 1282 1391 1719 1740 1902

Shalby Cash Flow

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Opening Cash & Cash Equivalents 27 9 12 12 5 8 6 56 12 27 35
Cash Flow from Operating Activities 5 60 14 43 55 79 19 68 20 -4 -0
Cash Flow from Investing Activities -98 -153 -237 1 -31 -51 -60 -61 38 -36 -97
Cash Flow from Financing Activities 75 96 222 -51 -21 -30 90 -50 -151 48 84
Net Cash Inflow / Outflow -19 3 -0 -6 3 -2 49 -43 -93 8 -13
Closing Cash & Cash Equivalent 9 12 12 5 8 6 56 12 27 35 22

Shalby Ratios

# Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Earnings Per Share (Rs) 0 0 3.65 2.93 2.55 3.93 5.01 6.31 7.83 0.58 3.48
CEPS(Rs) 5.45 5.19 5.74 6 5.89 7.33 8.97 10.79 12.64 6.3 9.74
DPS(Rs) 0 0 0 0.5 0.5 1 1 1.2 1.2 0 0
Book NAV/Share(Rs) 0 0 69.57 72.2 74 77.28 81.13 86.37 93.06 92.2 93.38
Core EBITDA Margin(%) 19.13 22.08 20.88 18.06 17 20.27 17.39 17.17 19.13 12.4 12.71
EBIT Margin(%) 15.97 19.01 17.49 12.89 13.17 13.83 12.4 13.99 15.62 8.88 8.93
Pre Tax Margin(%) 12.37 15.6 14.21 10.9 11.65 12.78 11.32 12.68 13.73 5.13 5.31
PAT Margin (%) 12.51 8.87 10.36 6.85 5.67 9.83 7.72 8.41 8.94 0.18 3.04
Cash Profit Margin (%) 16.41 14.02 16.41 14.02 13.06 18.37 13.86 14.38 14.54 6.23 9.17
ROA(%) 8.49 4.61 4.42 3.12 2.72 4.05 4.6 5.06 5.37 0.11 1.9
ROE(%) 19.5 12.6 7.81 4.13 3.49 5.19 6.31 7.51 8.67 0.19 3.48
ROCE(%) 13.34 12.21 9.15 6.94 7.49 6.85 9.08 10.72 12.23 7.07 6.88
Receivable days 33.29 36.67 40.8 52.21 66.06 80.28 51.09 47.01 49.06 53.7 64.54
Inventory Days 8.37 8.53 9.51 9.82 10.51 16.21 37.64 69.5 82.21 93.09 111.22
Payable days 4430.53 433.29 415.03 489.09 401.5 619.39 761.23 492.96 624.41 394.9 297.82
PER(x) 0 0 56.05 44.09 18.13 25.69 23.31 21.33 30.57 342.2 36.48
Price/Book(x) 0 0 2.94 1.79 0.63 1.31 1.44 1.56 2.57 2.15 1.36
Dividend Yield(%) 0 0 0 0.39 1.08 0.99 0.86 0.89 0.5 0 0
EV/Net Sales(x) 1.02 1.23 5.83 3.12 1.1 2.44 1.87 1.96 3.06 2.32 1.65
EV/Core EBITDA(x) 5.12 5.11 24.79 15.54 5.33 10.89 9.75 9.79 14.43 15.53 10.95
Net Sales Growth(%) 5.44 11.49 16.75 22.29 5.32 -11.49 62.21 15.16 16.01 16.41 5.01
EBIT Growth(%) -4.43 32.68 7.41 -9.88 7.68 -7.08 45.45 29.91 29.48 -33.77 5.51
PAT Growth(%) 47.93 -20.97 36.47 -19.19 -12.85 53.56 27.4 25.4 23.38 -97.7 1706.46
EPS Growth(%) 0 0 0 -19.6 -12.86 53.67 27.66 25.9 24.07 -92.6 500.66
Debt/Equity(x) 1.09 1.31 0.15 0.09 0.08 0.05 0.18 0.15 0.31 0.43 0.54
Current Ratio(x) 0.7 0.8 1.7 2.23 2.81 3.32 2.56 2.66 1.71 1.45 1.25
Quick Ratio(x) 0.62 0.76 1.62 2.09 2.62 3.03 1.86 1.71 0.98 0.74 0.6
Interest Cover(x) 4.44 5.58 5.34 6.49 8.66 13.13 11.51 10.66 8.28 2.36 2.47
Total Debt/Mcap(x) 0 0 0.05 0.05 0.12 0.04 0.12 0.1 0.12 0.2 0.39

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR +5% +12% +21% +15%
Operating Profit CAGR +6% +2% +12% +11%
PAT CAGR +1650% -20% -4% 0%
Share Price CAGR -50% -17% -5% —
ROE Average +3% +4% +5% +7%
ROCE Average +7% +9% +9% +9%

Shalby Shareholding Pattern

Latest · Jun 2026
100% held
Promoters 74.33 %
FII 4.46 %
DII (MF + Insurance) 0.3 %
Public (retail) 20.91 %
# Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Promoter 74.2474.2574.2574.2774.2774.2774.3374.3374.3374.33
FII 4.885.355.374.654.545.24.644.474.364.46
DII 00.060.090.140.180.20.20.20.250.3
Public 20.8920.3520.2920.9421.0120.3320.8421.0121.0720.91
Others 0000000000
Total 100100100100100100100100100100

Shalby Peer Comparison

Hospital & Healthcare Services Edit Columns

Shalby Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Shalby Pros & Cons

Pros

  • Debtor days have improved from 394.9 to 297.82days.

Cons

  • Company has a low return on equity of 4% over the last 3 years.
  • The company has delivered a poor profit growth of -3% over past five years.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp